You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.
In Science this week: genetic overlap between five psychiatric disorders, and more.
Using post-mortem data, researchers explored similarities and differences between autism, schizophrenia, bipolar disorder, alcoholism, and depression.
Business Insider reports that researchers are making headway in linking genetic variants to mental illness risk.
Genetic testing can help identify why people aren't responding to certain mental health medications, according to the Philadelphia Inquirer.
In the African American arm of a new GWAS, a risk variant in the SEMA3A gene was associated with both alcohol dependence disorder and major depressive disorder.
The Seattle Times writes that pharmacogenomics testing can help choose medications that may work best for people with depression.
The company launched the RxMatch Antidepressant Panel as the first step to grow beyond precision oncology and offer genomic assays for a wider range of diseases.
An Australian team searches for genetic alterations linked to depression in hopes of developing personalized treatments, the Sydney Morning Herald reports.
Researchers from Hong Kong imputed transcriptomes from GWAS data and compared them to drug-induced gene expression profiles.
An analysis of blood donations suggests SARS-CoV-2 was present in the US weeks earlier than thought, according to NPR.
The Guardian reports that DeepMind Technologies' AlphaFold can predict how proteins fold.
CNBC reports that a US Centers for Disease Control and Prevention advisory panel is to vote on how to distribute COVID-19 vaccines.
In PNAS this week: targeting progesterone signaling in ovarian cancer, LINE-1 retrotransposition events in adenocarcinomas, and more.